Stewart Smith, MD
Ophthalmology · Wilmington, DENPI 1306841010
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $5,078 of the $5,720 with a category attached, or 88.8%. 24 manufacturers reported payments, led by Mallinckrodt Hospital Products Inc. at 25.3% of the total. Among ophthalmology clinicians in DE with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 217 payments — averaging $26.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Mallinckrodt Hospital Products Inc.$1K
- Bausch & Lomb Americas Inc.$1K
- Alcon$575
- AbbVie$313
- Amgen$302
- Bausch & Lomb, A Division Of Bausch Health US, LLC$298
- plus $2K from 18 others
What the payments were for
- Consulting fees$57510%
- Speaking & faculty fees$260%
- Food & beverage$5,07889%
- Gifts$190%
- Other$220%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Mallinckrodt Hospital Products Inc. | 51 | $1,446 |
| Bausch & Lomb Americas Inc. | 25 | $1,034 |
| Alcon | 22 | $575 |
| AbbVie(2 entities) | 16 | $313 |
| Amgen | 13 | $302 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 18 | $298 |
| Johnson & Johnson Surgical Vision, Inc. | 6 | $288 |
| Dompe US, Inc. | 9 | $240 |
| Sun Pharmaceutical Industries Inc. | 7 | $177 |
| Eyevance Pharmaceuticals LLC | 9 | $125 |
| Lensar, Inc. | 2 | $124 |
| Sight Sciences, Inc. | 8 | $123 |
| Kala Pharmaceuticals, Inc. | 5 | $120 |
| Novartis | 5 | $104 |
| Tarsus Pharmaceuticals, Inc. | 4 | $97 |
| ANI Pharmaceuticals, Inc. | 4 | $70 |
| Harrow Eye, LLC | 3 | $69 |
| Rxsight Inc | 2 | $47 |
| NEW World Medical,inc. | 1 | $40 |
| Carl Zeiss Meditec USA, Inc. | 2 | $40 |
| Eyepoint US, Inc. | 2 | $39 |
| Carl Zeiss Meditec AG | 1 | $19 |
| Oyster Point Pharma, Inc. | 1 | $18 |
| Akorn Operating Company LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ENVISTA ENVY$575
- Tecnis IOL$150
- VERITAS Vision System$150
- AcrySof$132
- ACTHAR$125
- TEPEZZA$124
How this compares
$5,720 in reported general payments places this provider in the 90th percentile of 49 ophthalmology providers in Delaware.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OxervateCenegermin-Bkbj | 51 | $1,893,043 |
| RestasisCyclosporine | 30 | $45,991 |
| Prednisolone Acetate | 769 | $39,865 |
| VyzultaLatanoprostene Bunod | 72 | $31,344 |
| VevyeCyclosporine | 12 | $13,342 |
| Alphagan PBrimonidine Tartrate | 35 | $13,175 |
| Cyclosporine | 11 | $11,914 |
| Ofloxacin | 577 | $8,036 |
| LumiganBimatoprost | 18 | $7,384 |
| Loteprednol Etabonate | 29 | $5,844 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 19 | $5,719 |
| Brimonidine Tartrate | 43 | $2,813 |
| Travoprost | 13 | $2,383 |
| Timolol Maleate | 60 | $1,412 |
| Doxycycline Hyclate | 41 | $1,170 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Dompe US, Inc.Oxervate | $240 | $1,893,04351 claims |
| AbbVieRestasis, Alphagan P, Lumigan | $313 | $66,55083 claims |
| Bausch & Lomb Americas Inc.Vyzulta | $1,034 | $31,34472 claims |
| Harrow Eye, LLCVevye | $69 | $13,34212 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $298 | $5,84429 claims |
| AlconSimbrinza | $575 | $5,71919 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 49 ophthalmology providers in Delaware.
Other ophthalmology in Wilmington
- Jeffrey MinkovitzWilmington$7K
- Heather DealyWilmington$6K
- Richard SherryWilmington$5K
- Michael BrosmanWilmington$5K
- Brian ToussaintWilmington$2K
- Sean ConsidineWilmington$2K
- Tabassum AliWilmington$2K
- Paula KoWilmington$2K
- Harry LebowitzWilmington$2K
- Charles WangWilmington$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.